|
KMID : 0923620210210010008
|
|
Immune Network
2021 Volume.21 No. 1 p.8 ~ p.8
|
|
|
Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
|
|
Hong Jae-Woo
Jhun Hyun-Jhung
Choi Yeo-Ok
Taitt Afeisha S.
Bae Su-Young
Lee Young-Min
Song Chang-Seon
Yeom Su-Cheong
Kim Soo-Hyun
|
|
|
Abstract
|
|
|
|
The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of December 2020, there have been 80.2 million confirmed patients, and the mortality rate is known as 2.16% globally. A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry. We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell. Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials. Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world. In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target.
|
|
|
KEYWORD
|
|
|
COVID-19, SARS-CoV-2, Spike glycoprotein, Angiotensin-converting enzyme 2, Molecular targeted therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|